Our mission & values
We are on a mission to harness the microbiome to transform the lives of patients. To achieve our mission, we have assembled a team of multi-disciplinary experts and built a culture that values collaboration and a diversity of perspectives and ideas. Our team is united by our collective desire to develop a novel class of therapeutics for patients and families battling serious conditions linked to disruption of the microbiome.
Built into our company DNA is a strong commitment to living our core values and utilizing them to guide our decisions and actions.
We have an unwavering commitment to putting the needs of patients first in everything we do
We work relentlessly to achieve our mission and deliver on our commitments
We maintain open minds and constantly work to expand our knowledge
We push scientific boundaries and ourselves
We are committed to nurturing a strong, diverse community within Finch and giving back to the external communities we are a part of
Our leadership team
Our leadership team is comprised of seasoned biotech executives and recognized leaders in the microbiome field—clinicians and scientists that have paved the way for a new class of therapeutics with the potential to treat a wide range of conditions linked to disruption of the microbiome. Our leadership team combines decades of experience in the areas of microbiology, data science, clinical research, and the manufacture and commercialization of complex biologics.
We believe that collaboration is key to unlocking the full potential of the microbiome. As such, we have partnerships with leading clinician researchers and institutions driving human microbiome research around the globe—from the United States to Australia and China.
We are also proud to partner with Takeda Pharmaceuticals on the development of microbiome drugs for individuals with ulcerative colitis and Crohn’s disease, the most common types of inflammatory bowel disease (IBD). Our partnership, initially focused on the development of FIN-524 for ulcerative colitis, was expanded in 2019 to include the initial development of a potential microbiome product candidate, FIN-525, for Crohn’s disease. Takeda’s deep expertise in gastroenterology and IBD is an ideal complement to our own expertise in microbiome therapeutics.
Collaborate with us
We actively partner with academic researchers to catalyze discoveries in the microbiome. Please reach out to us if you would like to explore opportunities to work together.Contact us
To read more about our collaboration with Takeda:
Finch Therapeutics & Takeda Expand Collaboration to Develop Microbiome Therapeutics Using Finch’s Human-First Discovery Platform
Finch Therapeutics and Takeda Announce Global Collaboration to Develop Microbiome Therapeutics in Inflammatory Bowel Disease